

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

The logo for EuroEyes, featuring the word "EuroEyes" in white sans-serif font on a dark blue rectangular background.

EuroEyes International Eye Clinic Limited

德視佳國際眼科有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1846)

VOLUNTARY ANNOUNCEMENT IMPACT OF THE CORONAVIRUS DISEASE 2019 (COVID-19) OUTBREAK ON BUSINESS OPERATIONS

This announcement is made by EuroEyes International Eye Clinic Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) on a voluntary basis for the purpose of keeping the shareholders and potential investors of the Company informed of the impact of the coronavirus disease 2019 (“**COVID-19**”) outbreak on the Group’s business operations.

Business and Operation in the PRC

In light of the COVID-19 outbreak, many provinces and municipalities in the People’s Republic of China (the “**PRC**”) have implemented emergency public health measure and taken various actions to prevent the spread of the COVID-19 outbreak, which include, among other things, imposing conditions and restrictions on travel and resumption of work. The Group currently operates six clinics in the PRC and given the COVID-19 outbreak, the Group’s operations in the PRC were suspended at the end of January 2020 but have gradually resumed from mid-February 2020 to early March 2020.

During the suspension period, the Group took proactive measures in response to the situation in order to establish a solid foundation for business recovery. These measures include, among other things, conducting online consultations, focusing on online marketing, and communicating with the Group’s patients on a regular basis. By implementing these measures, the directors of the Company (the “**Directors**”) believe that it has taken appropriate and reasonable steps to minimise the adverse impact arising from the COVID-19 outbreak on the Group’s business in the PRC.

As of the date of this announcement, all of the Group’s clinics in the PRC (other than the Group’s Beijing (West) clinic) have resumed operations in line with the local regulations in the PRC. The Group’s Beijing (West) clinic will resume operations pending further directions from the relevant local authorities in the PRC.

To minimise contacts among the patients and the Group's employees, the Group's clinics in the PRC currently adopt the following preventive measures, including but not limited to, (i) operating on a reservation-only basis, (ii) inquiring patients' travel history, suspected symptoms and contact with suspected or confirmed cases in advance, (iii) taking strict measures on disinfection and cleaning of the clinics and consultation centres, (iv) closely monitoring the Group's employees for signs and symptoms of COVID-19, and (v) allowing the Group's employees to work remotely. At present, the Group's business in the PRC is being operated in an orderly manner.

As of the date of this announcement, to the best knowledge and information of the Directors, none of the Group's medical staff and other non-medical staff in the PRC has been diagnosed with COVID-19.

In addition, the construction of the Group's clinics in Chongqing and Fuzhou is currently progressing as scheduled, with no major adverse impact expected for the time being.

Business and Operation in Europe

As of the date of this announcement, the Group's business in Europe has not been materially affected by the COVID-19 outbreak. However, in view of the growing number of confirmed cases of COVID-19 in Europe, the Directors believe that the COVID-19 outbreak may have an adverse impact on the Group's operations in Europe.

In view of the effectiveness of the preventive measures applied in the Group's clinics in the PRC, the Group has implemented similar measures in the Group's clinics in Germany and Denmark. These measures include, but are not limited to, (i) operating on a reservation-only basis, (ii) postponing all non-emergency post-operation control, (iii) inquiring patients' travel history, suspected symptoms and contact with suspected or confirmed cases in advance, (iv) taking strict measures on disinfection and cleaning of the clinics and consultation centres, (v) closely monitoring the Group's employees for signs and symptoms of COVID-19, and (vi) allowing the Group's employees to work remotely. The Group strives to ensure that effective preventive measures are implemented in its clinics and consultation centres.

As of the date of this announcement, to the best knowledge and information of the Directors, none of the Group's medical staff and other non-medical staff in Europe has been diagnosed with COVID-19.

Continuity of the Business

The COVID-19 outbreak is expected to have some impact on the Group's business operations, but it is still premature to assess or estimate the overall impact on the Group's financial performance given the rapidly changing situation. As of the date of this announcement, the Directors believe that the COVID-19 outbreak is not expected to have a significant adverse impact on the Group's continuity of its business.

The Group will continue to regularly monitor the development of the COVID-19 outbreak and assess its impact on the operations and financial performance of the Group. The Group will take appropriate measures as necessary and make further announcement as and when appropriate.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
EuroEyes International Eye Clinic Limited
Leung Ting Cheung
Company Secretary

Hong Kong, 19 March 2020

As at the date of this announcement, the board of Directors comprises Dr. Jørn Slot Jørgensen, Dr. Markus Braun, Dr. Ralf-Christian Lerche, Prof. Dr. Thomas Friedrich Wilhelm Neuhann, Mr. Jannik Jonas Slot Jørgensen as executive Directors; Mr. Marcus Huascar Bracklo as non-executive Director; Mr. Hans Helmuth Hennig, Mr. Zhengzheng Hu and Mr. Philip Duncan Wright as independent non-executive Directors.